Mayo Clinic Laboratory and Pathology Research Roundup: Oct. 16

By Kelley Luedke • October 16, 2017

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.

Featured Abstract

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. Mayo Clinic researchers conducted a study to determine the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX. Based on the results, the deficient MMR phenotype remains a favorable prognostic factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy. The review was published in Jama Oncology.

Published to PubMed This Week

• Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement
  JAMA Internal Medicine
• Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion
  Cancer Research
• Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer
  Cell Reports
• Improving the Specificity of Cardiac Biomarkers-the Early Development of Cardiac Troponin I (cTnI) Assays
  Clinical Chemistry
• Is the Blood-Brain Barrier Really Disrupted in All Glioblastomas? - A Critical Assessment of Existing Clinical Data
  Neuro Oncology
• Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02
  Neuro Oncology
• Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study
  International Journal of Epidemiology
• Renal Pyelocalyceal Squamous Cell Carcinoma
  Mayo Clinic Proceedings
• Alcohol Consumption, Variability in Alcohol Dehydrogenase Genes and Risk of Renal Cell Carcinoma
  International Journal of Cancer
• Blinatumomab-Induced Lineage Switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an Aggressive AML: Pre- and Post-Switch Phenotypic, Cytogenetic and Molecular Analysis
  Blood Cancer Journal
• Polypoid Fibroadipose Tumors of the Esophagus: 'Giant Fibrovascular Polyp' or Liposarcoma? A Clinicopathological and Molecular Cytogenetic Study of 13 Cases
  Modern Pathology
• Clinical Heterogeneity of Diffuse Large B Cell Lymphoma Following Failure of Front-Line Immunochemotherapy
  British Journal of Haematology
• Dexamethasone, Rituximab and Cyclophosphamide for Relapsed and/or Refractory and Treatment-Naïve Patients with Waldenstrom Macroglobulinemia
  British Journal of Haematology
• The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors
  American Journal of Surgical Pathology
• Therapy Related-Chronic Myelomonocytic Leukemia (CMML): Molecular, Cytogenetic and Clinical Distinctions from de novo CMML
  American Journal of Hematology
• Crohn's Disease of the Pouch: A True Diagnosis or an Oversubscribed Diagnosis of Exclusion?
  Diseases of the Colon & Rectum
• Analytical Comparison of Three Different Versions of a High-Sensitivity Cardiac Troponin I Assay Over 10 Years
  Clinica Chimica Acta

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.